(Q41511106)

English

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

scientific article published on January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

Paolo M. Comoglio

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Eugenia R Zanella

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesco Galimi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesco Sassi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Giorgia Migliardi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesca Cottino

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Simonetta M Leto

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Andrea Bertotti

15

object named as

Andrea Bertotti

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Barbara Lupo

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jessica Erriquez

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Eva Budinská

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Livio Trusolino

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sabine Tejpar

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

0 references

publication date

1 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Science Translational Medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

272

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

272ra12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Which drug, and when, for patients with BRAF-mutant melanoma?

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

The insulin and insulin-like growth factor receptor family in neoplasia: an update

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Targeting the ERBB family in cancer: couples therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

LAS: a software platform to support oncological data management

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Cytogenetics and DNA amplification in colorectal cancers

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Identifiers

10.1126/SCITRANSLMED.3010445

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41511106&oldid=1535989431"